| Page 4 | Kisaco Research
 

Tony Watson

Director of Procurement
Accord Healthcare

Tony Watson

Director of Procurement
Accord Healthcare

Tony Watson

Director of Procurement
Accord Healthcare
 

Edith Tea

Environment & Climate Change Specialist (Tony's Open Chain)
Tony's Chocolonely

Edith Tea

Environment & Climate Change Specialist (Tony's Open Chain)
Tony's Chocolonely

Edith Tea

Environment & Climate Change Specialist (Tony's Open Chain)
Tony's Chocolonely
 

Vanessa Maire

Global Director, Head of Regenerative Agriculture
Unilever

Vanessa Maire

Global Director, Head of Regenerative Agriculture
Unilever

Vanessa Maire

Global Director, Head of Regenerative Agriculture
Unilever
 

Ellen Braug

European Patent Attorney- UPC Representative
Plasseraud

Ellen Braug

European Patent Attorney- UPC Representative
Plasseraud

Ellen Braug

European Patent Attorney- UPC Representative
Plasseraud
 

Camila Vislie

Partner
Thommessen

Camila Vislie

Partner
Thommessen

Camila Vislie

Partner
Thommessen
 

James Zhu

Partner
JunHe LLP

James Zhu

Partner
JunHe LLP

James Zhu

Partner
JunHe LLP
 

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann
 

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

The UPC’s Milan Division has drawn new lines on procedural efficiency- finding both excessive invalidity attacks and late-filed arguments unacceptable. This 15 minute update examines the bioMérieux v Labrador decision and its implications for how defendants and plaintiffs must now calibrate their litigation strategy before the UPC.

Author:

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann
 

Daniel Haders, PhD

Chief Executive Officer & Founder
Model Medicines

Daniel Haders, PhD

Chief Executive Officer & Founder
Model Medicines

Daniel Haders, PhD

Chief Executive Officer & Founder
Model Medicines